Novartis to Acquire Endocyte for $2.1B, Expanding RLT Pipeline in Prostate Cancer

Novartis has agreed to acquire Endocyte for $2.1 billion, the companies said today, in a deal that expands the buyer’s radioligand therapy (RLT) pipeline of targeted oncology treatments with a Phase III candidate and several early-stage candidates.Endocyte is a developer of targeted therapies that combine the company’s small molecule drug conjugate (SMDC) technology with companion imaging agents designed to assist in therapy selection.Endocyte’s lead candidate is 177 Lu-PSMA-61